"studyAcronym","uuid:ID","id","studyTitle","studyVersion","studyRationale"
"LZZT","cf284827-4ec9-4082-a529-643c7deb42f2","StudyVersion_1","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
